Ann: PAR Appoints Business Development Consultant, page-110

With deals apparently hard to come by and our financial situation, now might be the time for Bene to step in with either joint OA indication funding offer and/or part ownership (perhaps as one party in a consortium). Part ownership would also allay niggles from interested pharma about exclusivity and supply, and let's face it, pharma will require Bene to be part of any deal negotiations. I'm assuming, of course, they aren't already shareholders under some sneaky corporate setup.

This is from 2021 when they signed co-finding agreement for indications beyond OA and MPS.
"“Bene is excited by the imminent commencement of the Phase 3 program for osteoarthritis and will be assisting Paradigm in any way possible to achieve the goal of successful registration and commercialisation of Zilosul for OA.” - bene pharmaChem co-managing director Dr Harald Benend

Of course, they may just be waiting around until everything falls over and they can just pick up the bones and get things across the finish line!